louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05220904: Perceptual Learning Improve Visual Function in Patients With Keratoconus
Official title: A Randomized Controlled Clinical Study of Perceptual Learning Improving Visual Function in Patients With Keratoconus
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Keratoconus, Stable
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2022-02-02
Enrollment: 54
Sex: ALL
Minimum age (years): 9
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This project aims at non-progressive keratoconus patients with unsatisfactory visual acuity corrected by spectacles, and explores the effectiveness and maintenance of visual acuity improved by perceptual learning.


Eligibility criteria: Inclusion Criteria:

1. Aged 9 years or older;
2. Has been diagnosed as Keratoconus,BAD-D≥2.6;
3. Change of Kmax \< 1.0 D and change of BAD-D \<0.4175 betweem the last two Pentacam result;
4. The best corrected visual acuity of both eyes was between 0.1 and 1.0;
5. Has voluntarily agreed to participate in the study by signing the statement of informed consent.

Exclusion Criteria:

1. Has history of acute keratoconus;
2. Has other eye diseases or other diseases/conditions causing vision loss;
3. Has eye surgery history in the past 1year;
4. Is currently using local/systemic medications or other interventions that may affect visual function;
5. Receiving other treatments that may affect the results of this study, such as contact lenses during the study;
6. Has any known neurological diseases;
7. Participating in other studies currently that may affect the results of this study;
8. Study other reasons that the physician considers inappropriate for inclusion in the program.

Primary outcomes:
measure: 3-months corrected visual acuity
timeFrame: baseline；3 months.
Secondary outcomes:
measure: corrected visual acuity of other time frame
timeFrame: 6,9,15 months
measure: ucorrected visual acuity (UCVA)
timeFrame: 3,6,9,15 months
measure: contrast sensitivity function (CSF)
timeFrame: 3,6,9,15 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University
name: Xiao Yang, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT03469401: Evaluation of BD Glucan in Peritoneal Fluid for the Diagnosis of Fungal Peritonitis
Official title: Evaluation of the Detection of B D Glucan in Peritonitis Fluid in Intensive Care Unit (ICU) Patients With Peritonitis for the Diagnosis of Fungal Peritonitis, Compared to Routine Microbiology Diagnosis Method. The PERICAND Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-03-19
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis

Brief summary: Invasive candidiasis has a high mortality rate, around 40%. Outcome remains tightly linked to the time of treatment administration. Routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). It is important to develop diagnostic tools to initiate antifungal therapy as early as possible.

The B D glucan detection, one of the major components of the candida cell wall, can be useful for a early diagnosis.

There are several techniques on the market for the detection of glucan. In Europe and America, the most used is Fungitell (Associated of Cape Cod, Inc).

There is several studies about the use of such kits for fungemia. A number of studies are reporting evidences of a early diagnosis.

But, in medical literature, there isn't study focused on the detection of B D glucan in peritoneal fluid for Candida peritonitis diagnosis.


Eligibility criteria: Inclusion Criteria:

* Aged ≥ 18 years old
* written informed consent for inclusion in the study
* stay in intensive care unit
* diagnosed with a peritonitis
* peritoneal fluid collected by a surgery or radiology procedure, analysed at bacteriology laboratory of l'institut des agents infectieux, l'hôpital de la Croix Rousse

Exclusion Criteria:

* Pregnant woman
* Moribund patient

Primary outcomes:
measure: Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud
Study officials:
affiliation: Hospices Civils de Lyon
name: Florent WALLET, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06566001: Comparative Study Between Socket Shield Technique Versus Allograft Buccal Sheet Technique on Alveolar Bone Resorption After Immediate Implant Placement
Official title: Comparative Study Between Socket Shield Technique Versus Allograft Buccal Sheet Technique on Alveolar Bone Resorption After Immediate Implant Placement in Esthetic Region ( Randomised Clinic Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Loss in Jaw
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-08-22
Enrollment: 22
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 22 patient where divided randomly into 2 groups : control group did dental implant utilizing socket shield , while study group did dental implant with allogenic bone graft there is no significant bone loss between the two groups after 4 month follow up


Eligibility criteria: Inclusion Criteria:

- patient has remaining root in upper anterior without lesion

Exclusion Criteria:

periapical lesion under the tooth

Primary outcomes:
measure: measure bone loss by CBCT
timeFrame: 4 month
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university
Study officials:
References:
Clinical trial NCT01302301: Endolumenal Partial Myotomy for Esophageal Motility Disorders
Official title: Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Atypical Primary Motility Disorders Such as Achalasia and Esophageal Spasm
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Esophageal Motility Disorders
Keywords: endolumenal myotomy, per oral endoscopic myotomy
Lead sponsor: The Oregon Clinic
Sponsor class: OTHER
First posted: 2011-02-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Achalasia and esophageal spasm are primary esophageal motility disorders where the lower esophageal sphincter fails to relax in response to swallowing with no well understood underlying cause. Surgical myotomy represents an appropriate therapeutic option. The purpose of this study is to evaluate flexible endoscopic myotomy a novel therapeutic approach to overcome the need for invasive surgery.

Detailed description: In this study, the investigators propose the use of a recent endolumenal technique for partial myotomy in patients suffering from primary esophageal motility disorders.

Under general anesthesia patients will have upper endoscopy. Submucosal injection and mucosal incision is created for entry into the submucosal space. A submucosal tunnel is then created using a needle knife or blunt dissection as appropriate. Dissection will continue distally beyond the lower esophageal sphincter. The inner circular muscle fibers will then be divided to achieve an adequate myotomy length. The mucosal entry is then closed appropriately.

Results will be compared to historical data of conventional Heller myotomies.

Eligibility criteria: Inclusion Criteria:

* Candidate for elective Heller myotomy
* Ability to undergo general anesthesia
* Ability to give informed consent

Exclusion Criteria:

* Previous mediastinal or esophageal surgery
* Contraindications for EGD

Primary outcomes:
measure: Esophageal Function Tests
timeFrame: 6 month
Secondary outcomes:
measure: Quality of life score
timeFrame: 6 months
Other outcomes:
Locations:
city: Portland
country: United States
facility: Providence Portland Medical Center
state: Oregon
Study officials:
References:
citation: Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki M, Satodate H, Odaka N, Itoh H, Kudo S. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy. 2010 Apr;42(4):265-71. doi: 10.1055/s-0029-1244080. Epub 2010 Mar 30.
Clinical trial NCT05310201: Impact of the Be Well Care Well Program on Early Care Education Teachers
Official title: Targeting Teacher Stress and Well-being to Improve Child Outcomes: Impact of the Be Well Care Well Program
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Burnout, Caregiver
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
Collaborators: name: University of Delaware
First posted: 2022-04-04
Enrollment: 244
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study will address the following specific aims: (1) assess the impact of the BWCW program on teacher stress and physical activity, (2) Examine feasibility of collecting cortisol.


Eligibility criteria: Inclusion Criteria:

Teachers that meet the following criteria will be included:

1. currently employed as a teacher or assistant teacher at a participating ECE center;
2. ages 18 or older;
3. men or women;
4. able to speak, read, and write English.

Exclusion Criteria:

None

Primary outcomes:
measure: Change in score of Devereux Adult Resilience Survey
timeFrame: Baseline and 1 year follow-up
measure: Change in score of Child Worker Job Stress Inventory
timeFrame: Baseline and 1 year follow-up
measure: Change in score on the Lifestyle Questionnaire
timeFrame: Baseline and 1 year follow-up
measure: Change in score on the Early Childhood Job Satisfaction Survey
timeFrame: Baseline and 1 year follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Charleston
country: United States
facility: MUSC Department of Psychiatry
state: South Carolina
Study officials:
References:
Clinical trial NCT00393601: Chart Review of Laparoscopic Radical Cystectomy
Official title: Retrospective Chart Review of Laparoscopic Radical Cystectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Laparoscopic Radical Cystectomy
Keywords: Cystectomy
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2006-10-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Those who have undergone a laparoscopic radical cystectomy performed by Dr. David Ornstein.

Brief summary: The investigator intends to review retrospective de-identified data of patients who have had Laparoscopic Radical Cystectomies by the Department of Urology at UCIMC.

Detailed description: The investigator fills out a standardized form for each patient undergoing a laparoscopic radical cystectomy.

Eligibility criteria: Inclusion Criteria:

* Review information on patients who had laparoscopic Radical cystectomy at UCIMC

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Orange
country: United States
facility: University of California, Irvine Medical Center
state: California
Study officials:
affiliation: University of California, Irvine
name: Atreya Dash, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03854604: Perfusion Index as an Objective Measure for Postoperative Pain Assessment in Pediatric Patients.
Official title: Evaluation of Perfusion Index as an Objective Measure for Postoperative Pain Assessment in Pediatric Patients Undergoing Adenotonsillectomy. An Observational Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-02-26
Enrollment: 50
Sex: ALL
Minimum age (years): 3
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children 3-7 years, ASA physical status I or II, undergoing Adenotonsillectomy will be included

Brief summary: It has been demonstrated that infants and children experience pain in a similar manner to adults, however it used to be undertreated when compared to adult.

Perfusion Index (PI) derived from pulse plethysmography waveform, represents a ratio of pulsatile signal (during arterial inflow) to non-pulsatile signal. PI can represent the peripheral perfusion dynamics due to change of peripheral vasomotor tone. Low PI values suggest peripheral vasoconstriction and high PI values suggest peripheral vasodilation.

The sympathetic nervous system is inherently involved in the pathophysiological responses evoked by painful stimulation.

In the current study, investigators hypothesise that the PI could be a good objective tool for assessment of postoperative pain in children undergoing adenotonsillectomy.


Eligibility criteria: Inclusion Criteria:

1. ASA physical status I-II
2. Age 3 to 7 years
3. Children undergoing adenotonsillectomy.

Exclusion Criteria:

1. Parents' refusal.
2. Children with behavioral changes
3. Children with physical developmental delay
4. Children on treatment with sedative or anticonvulsant.

Primary outcomes:
measure: Correlation between postoperative (Children's Hospital of Eastern Ontario Scale ) CHEOPS score and postoperative perfusion index.
timeFrame: the time span between arrival to PACU and for at least two hours postoperative
Secondary outcomes:
measure: validity of perfusion index to predict postoperative pain and the need of rescue analgesia
timeFrame: he time span between arrival to PACU and for at least two hours postoperative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Abeer Ahmed
city: Cairo
country: Egypt
facility: Kasr Alainy Faculty of Medicine - Cairo university
city: Cairo
country: Egypt
facility: Anesthesia department - Faculty of medicine- Cairo University
Study officials:
References:
citation: Ahmed A, Lotfy A, Elkholy J, Abdelhamid B, Ollaek M. Perfusion index as an objective measure of postoperative pain in children undergoing adenotonsillectomy: a cohort study. J Clin Monit Comput. 2022 Jun;36(3):795-801. doi: 10.1007/s10877-021-00710-3. Epub 2021 Apr 23.
Clinical trial NCT01941004: Safety and Efficacy of Fingolimod in MS Patients in China
Official title: A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Multiple Sclerosis (Relapsing Remitting)
Keywords: multiple sclerosis (MS)
relapsing remitting multiple sclerosis (RRMS)
fingolimod
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2013-09-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China


Eligibility criteria: Inclusion Criteria:

-Patients must have relapsing remitting multiple sclerosis

Exclusion Criteria:

Patients with:

* History of chronic immune disease
* Certain cancers
* Uncontrolled diabetes
* Certain eye disorders -Negative for varicella
* zoster virus IgG antibodies
* Certain hepatic conditions
* Low white blood cell count
* On certain immunosuppressive medications or heart medications
* Certain heart conditions or certain lung conditions
* Inability to undergo MRI scans -Diagnosis of Neuromyelitis optica.
* Other protocol defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: number of new/newly enlarged T2 MRI lesions over 6 months
timeFrame: 6 months
Secondary outcomes:
measure: annualized relapse rate (ARR)
timeFrame: 6 months
measure: number of Gd-enhancing T1 lesions
timeFrame: 6 months
measure: Safety and tolerability of fingolimod 0.5 mg compared to placebo
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
Clinical trial NCT02420704: Effect of Endometrial Thickness on IVF Outcome
Official title: Effect of Endometrial Thickness on IVF Outcome: a Prospective Observational Study of Both Cleavage Stage and Blastocyst Stage Embryo Transfer Cycles
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Keywords: IVF
endometrial thickness
cleavage stage embryo
blastocyst stage embryo
Ongoing pregnancy rate
Lead sponsor: The First Affiliated Hospital of Zhengzhou University
Sponsor class: OTHER
First posted: 2015-04-20
Enrollment: 500
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients transfrred with at least two high quality cleavage stage embryos, or with at least one high quality blastocyst stage embryo.

Brief summary: Although many studies have evaluated the relationship between endometrial thickness and IVF outcome, the results are still controversial. We notice that, during our daily work, for patients undergoing cleavage stage embryo transfer, endometrial thickness seems to have a huge impact on IVF outcome; however, for blastocyst stage embryo transfers, IVF outcome seems to have little association with endometrial thickness. Thus, the aim of this prospective observational study is to explore the relationship between endometrial thickness and IVF outcome in patients undergoing cleavage stage and blastocyst stage embryo transfers, respectively.


Eligibility criteria: Inclusion Criteria:

* age between 22-38 years old;
* the first cycle of IVF treatment with standard long protocol;
* transfrred with at least two high quality cleavage stage embryos, or with at least one high quality blastocyst stage embryo.

Exclusion Criteria:

* PGD cycles;
* gamete donation cycles

Primary outcomes:
measure: Ongoing pregnancy rate
timeFrame: 12 weeks after embryo transfer
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University
state: Henan
Study officials:
affiliation: Reproductive Medical Centre
name: Yingpu Sun, M.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wu Y, Gao X, Lu X, Xi J, Jiang S, Sun Y, Xi X. Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration. Reprod Biol Endocrinol. 2014 Oct 9;12:96. doi: 10.1186/1477-7827-12-96.
citation: Zhao J, Zhang Q, Wang Y, Li Y. Endometrial pattern, thickness and growth in predicting pregnancy outcome following 3319 IVF cycle. Reprod Biomed Online. 2014 Sep;29(3):291-8. doi: 10.1016/j.rbmo.2014.05.011. Epub 2014 Jun 13.
citation: Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmeer BC, Broekmans FJ. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014 Jul-Aug;20(4):530-41. doi: 10.1093/humupd/dmu011. Epub 2014 Mar 23.
Clinical trial NCT01616004: Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject
Official title: Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-06-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether N2O (laughing gas) has an antinociceptive effects in healthy volunteers.

Detailed description: 10 healthy volunteers will come twice to the pain medicine unit, at 1 visit they'll get N2O and in the second visit they'll get air as placebo, they won't know what they're getting. During the visit they'll get heat stimulus using QST and will have to report their pain using eVAS (scale from 0 to 100 when 0 is no pain and 100 is the worst pain imagine).

Eligibility criteria: Inclusion Criteria:

* 18-50 years old
* women and men
* healthy

Exclusion Criteria:

* smokers
* medication use pregnant woman cardiovascular disease

Primary outcomes:
measure: Pain Scores on the Visual Analog Scale
timeFrame: August 2016
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center, Pain Medicine Unit
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: Silviu Brill, MD
role: PRINCIPAL_INVESTIGATOR
References: